Erythroid leukemia

Erythroid leukemia, historically referred to as acute erythroleukemia or FAB M6, is a rare and aggressive hematologic malignancy affecting the hematopoietic system, predominantly involving the bone marrow and peripheral blood It is characterized by the neoplastic proliferation of immature erythroid precursors showing prominent maturation arrest, dyserythropoiesis, and a frequent association with complex cytogenetics and high-risk genomic features such as TP53 mutations

Erythroid leukemia, historically referred to as acute erythroleukemia or FAB M6, is a rare and aggressive hematologic malignancy affecting the hematopoietic system, predominantly involving the bone marrow and peripheral blood

It is characterized by the neoplastic proliferation of immature erythroid precursors showing prominent maturation arrest, dyserythropoiesis, and a frequent association with complex cytogenetics and high-risk genomic features such as TP53 mutations

It is characterized by the neoplastic proliferation of immature erythroid precursors showing prominent maturation arrest, dyserythropoiesis, and a frequent association with complex cytogenetics and high-risk genomic features such as TP53 mutations Clinically, bone marrow replacement by leukemic erythroblasts impairs normal hematopoiesis, leading to severe pancytopenia manifested by fatigue, heightened infection risk, mucocutaneous bleeding, and systemic constitutional symptoms

Clinically, bone marrow replacement by leukemic erythroblasts impairs normal hematopoiesis, leading to severe pancytopenia manifested by fatigue, heightened infection risk, mucocutaneous bleeding, and systemic constitutional symptoms